Oseltamivir-induced bradycardia in an adult patient

Abstract

The use of Oseltamivir, the first neuraminidase inhibitor available orally, has increased tremendously since the first pandemic of H1N1 influenza virus in 2009, as a mean of prevention as well as treatment of influenza. Its use has been associated with common side effects such as nausea and vomiting. However, few data is published concerning cardiovascular side effects that could lead to some serious complications. This case report presents a young healthy woman who developed sinus bradycardia while being on Oseltamivir therapy.